Guernsey’s success was soon emulated around the world with numerous variations of the cellular vehicle springing up, first in other international insurance domiciles, and latterly onshore notably in the US and UK.
In this GCP Short, produced in partnership with MAXIS Global Benefits Network, we explore findings from the network's latest whitepaper on GLP-1s, often known as weight-loss drugs.
